MBX Biosciences eases after stock offering announced

MBX Biosciences

23/09/2025 15:54

** Shares of MBX Biosciences MBX.O down 4.5% at $19.11 on Tues as co looks to raise equity after its stock doubled in prior session

    ** MBX shares on Mon closed up 100% at $20 after co said its experimental drug, canvuparatide, met main goal in mid-stage trial for adults with chronic hypoparathyroidism, a hormone disorder that causes low calcium levels

    ** After the bell, Carmel, Indiana-based MBX announced 10 million share offering

    ** W

      ith ~33.6 mln shares outstanding, co has about $640 mln market cap

    ** JP Morgan, Jefferies, TD Cowen and Guggenheim are joint bookrunners for the offering

    **
    Separately, Oppenheimer hiked its PT from $38 to $80

    ** Avg rating among 7 analysts
    covering MBX is "strong buy" and median PT is $45, per LSEG data

      ** MBX
      went public last Sept after IPO of 10.2 mln shares priced at $16

(Lance Tupper is a Reuters market analyst. The views expressed are his own)

((lance.tupper@tr.com 1-646-279-6380))